Olympus (7733) AI Stock Analysis

• Market Cap: ¥1.68T
• Dividend Yield: 1.01%
• Average Volume (3M): 3.67M
• Price to Earnings (P/E): 20.2
• Beta (1Y): 0.74
• Revenue Growth: 0.42%
• EPS Growth: 34.76%
• Country: JP
• Employees: 28,838
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 12.87
• Shares Outstanding: 1,114,485,700
• 10 Day Avg. Volume: 4,971,740
• 30 Day Avg. Volume: 3,665,053
• PEG Ratio: -0.39
• Price to Book (P/B): 2.96
• Price to Sales (P/S): 2.23
• P/FCF Ratio: 15.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 70.6
• Revenue Forecast (FY): ¥998.30B

• Rating: 60 Neutral
• Price Target: ¥1,641.00 ▼(-17.68% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is supported primarily by solid profitability and an improving balance sheet, but is held back by very weak technical momentum (below major moving averages with negative MACD and low RSI) and only middling valuation support (P/E ~24.5 with a modest ~1.24% yield).

Positive Factors

High Profitability Margins

Sustained high gross and operating margins indicate durable product differentiation and pricing power in endoscopy systems. Strong margins support reinvestment in R&D, fund service networks, and provide buffer against cyclical volume declines, preserving long-term cash generation.

Recurring, Installed-Base Revenue Model

A business model combining capital equipment plus recurring consumables and service creates predictable aftermarket revenue and higher lifetime customer value. Installed base-driven consumable sales and service contracts provide structural revenue resilience and higher margin annuity streams.

Improving Balance Sheet and Manageable Leverage

A lower, improving debt-to-equity ratio and sizable equity give financial flexibility to fund product development and M&A, while a TTM ROE around 13% shows decent capital returns. Strengthening leverage reduces refinancing risk and supports long-term strategic moves.

Negative Factors

Stalled Top-Line Momentum

Flat TTM revenue despite a strong product portfolio suggests slower adoption or market saturation in key segments. Prolonged revenue stagnation can limit scaling of fixed-costs, reduce upside from consumables growth, and constrain R&D or commercial investments over months.

Uneven Cash Flow and FCF Volatility

Material swings in operating cash flow and free cash flow undermine predictable capital allocation. Volatility hampers consistent reinvestment, dividends or debt reduction plans and raises execution risk for multi-quarter initiatives, affecting durable financial stability.

Exposure to Procedure Volumes and Procurement Cycles

Reliance on hospital procedure volumes and tender-driven procurement creates structural revenue cyclicality and pricing pressure. Regulatory delays or competitive tender outcomes can reduce consumables and equipment demand, pressuring long-term revenue and margin sustainability.

Olympus Business Overview & Revenue Model

Company Description

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Olympus generates revenue through a diversified model that includes the sale of medical systems, life sciences, and industrial products. The medical systems segment is a significant revenue driver, with endoscopic and surgical products leading sales, supported by ongoing maintenance and service contracts. Revenue is also derived from life science products, including microscopes and imaging systems used in laboratories and research institutions. The industrial solutions segment contributes through inspection equipment and services for manufacturing and quality control. Key partnerships with hospitals, research institutions, and industrial clients enhance its market presence and revenue streams. Additionally, Olympus invests in R&D to innovate and expand its product offerings, contributing to long-term growth and profitability.

Olympus Financial Statement Overview

Summary

Above-average fundamentals: solid profitability (gross margin ~67%, operating margin ~15%) and improving/managed leverage (TTM debt-to-equity ~0.32). Offsets are flat TTM revenue versus the prior annual period and uneven earnings/free-cash-flow consistency (FCF ~half of net income; prior-year volatility).

Income Statement

TTM (Trailing-Twelve-Months) results show solid profitability with strong gross margin (~67%) and healthy operating margin (~15%), supporting a ~10% net margin. However, the growth profile has cooled (TTM revenue roughly flat vs the prior annual period), and profitability has been somewhat volatile over the last few years (e.g., unusually high net margin in FY2024 followed by normalization in FY2025/TTM). Overall, the earnings engine looks sound, but momentum and consistency are mixed.

Balance Sheet

Leverage appears manageable and improving, with debt-to-equity around ~0.32 in TTM (Trailing-Twelve-Months) versus higher levels historically (near ~0.90 in FY2021). Equity remains sizable relative to assets, and returns on equity are healthy in TTM (~13%), though below the elevated FY2024 level. The balance sheet is generally supportive, with the key watch item being that profitability swings can materially change returns and leverage metrics over time.

Cash Flow

Cash generation is positive in TTM (Trailing-Twelve-Months), with operating cash flow and free cash flow both solidly positive, but cash conversion is only moderate (free cash flow is about half of net income in TTM). The biggest concern is variability: FY2024 saw weak operating cash flow and negative free cash flow, followed by a strong rebound in FY2025 and steadier (but lower) TTM cash flow. Overall, the business can produce cash, but the reliability of free cash flow has been uneven.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	987.51B	997.33B	925.75B	881.92B	750.12B	730.54B
Gross Profit	654.09B	683.70B	583.63B	596.85B	571.70B	459.53B
EBITDA	215.16B	231.90B	112.10B	254.58B	209.97B	140.42B
Net Income	84.83B	117.86B	242.57B	143.43B	115.74B	12.92B
Balance Sheet
Total Assets	1.46T	1.43T	1.53T	1.51T	1.36T	1.18T
Cash, Cash Equivalents and Short-Term Investments	196.74B	252.53B	340.93B	169.33B	302.57B	217.48B
Total Debt	237.82B	229.10B	299.62B	340.06B	386.13B	355.26B
Total Liabilities	684.57B	681.09B	777.03B	867.07B	846.64B	785.54B
Stockholders Equity	773.35B	751.73B	757.19B	640.09B	510.17B	394.33B
Cash Flow
Free Cash Flow	63.99B	144.46B	-22.26B	27.87B	107.96B	64.89B
Operating Cash Flow	123.50B	190.46B	42.37B	98.49B	169.73B	124.12B
Investing Cash Flow	-90.63B	-65.47B	359.99B	-58.41B	-71.02B	-118.92B
Financing Cash Flow	-87.29B	-211.54B	-276.01B	-143.18B	-40.67B	40.80B

Olympus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1993.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7733, the sentiment is Negative. The current price of 1993.5 is above the 20-day moving average (MA) of 1708.45, above the 50-day MA of 1871.51, and above the 200-day MA of 1866.76, indicating a bearish trend. The MACD of -124.19 indicates Positive momentum. The RSI at 32.14 is Neutral, neither overbought nor oversold. The STOCH value of 28.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7733.

Olympus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7730	71 Outperform	¥165.12B	33.41	―	2.73%	5.10%	-26.13%
4543	69 Neutral	¥3.12T	24.33	9.31%	1.22%	7.68%	10.08%
7747	68 Neutral	¥893.08B	50.74	10.09%	0.82%	13.53%	-7.39%
6869	68 Neutral	¥917.95B	20.51	9.80%	1.88%	1.51%	-12.59%
8086	62 Neutral	¥259.41B	17.06	4.38%	2.03%	6.04%	733.13%
7733	60 Neutral	¥1.68T	20.24	13.13%	1.01%	0.42%	34.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Olympus Corporate Events

Olympus Taps Global MedTech Veteran Michael Parenti as Next CFO

Olympus has announced a planned change in its top finance leadership, with Michael Parenti set to become Executive Officer and Chief Financial Officer effective April 1, 2026, pending formal board approval in March. The move is part of a succession plan aimed at strengthening the company’s management structure and enhancing its financial management capabilities.

Parenti brings broad experience from senior finance roles at global MedTech and healthcare companies, including CFO positions in China and Japan for Johnson & Johnson and a group CFO role at Stryker. Olympus expects his global perspective and track record in complex, multicultural environments to support disciplined capital allocation, sustainable growth, and value creation, as the company reshapes its executive team under CEO Bob White.

The appointment will see current CFO Tatsuya Izumi step down from his role as Executive Officer and Chief Financial Officer. From April 1, 2026, Olympus’s management team will include Parenti as CFO alongside other function and division heads, reinforcing a globally oriented leadership bench in areas such as strategy, technology, manufacturing, and quality.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2140.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Slashes FY2026 Profit Outlook on Surgical Shipment Disruptions

Olympus has sharply revised down its earnings forecast for the fiscal year ending March 31, 2026, while keeping revenue guidance unchanged at ¥998 billion, underscoring mounting pressure on profitability despite stable top-line expectations. The company now expects operating profit to fall by 36.0% to 44.9% versus its prior outlook, with profit attributable to owners of the parent cut by up to roughly 47%, reflecting a deterioration from the previous year’s performance.

Management cited weaker-than-expected progress in the third quarter and shipment suspensions in the Surgical & Interventional Solutions Division as key reasons for the downgrade, and introduced forecast ranges to account for heightened uncertainty. The revisions, which mark a significant step down from both the earlier guidance and the prior year’s results, signal operational headwinds in core businesses and could weigh on investor sentiment as Olympus navigates a more challenging operating and competitive environment.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2140.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Reshapes Segment Structure as Q3 FY2026 Profitability Softens

Olympus reported consolidated financial data for the third quarter of the fiscal year ending March 31, 2026, showing revenue of ¥261.0 billion and operating profit of ¥24.1 billion from continuing operations, with margins pressured versus the previous year. Profit attributable to owners of the parent for the quarter reached ¥14.2 billion, while foreign exchange provided only a modest tailwind compared with the prior year.

The company has reorganized its former Endoscopic and Therapeutic Solutions divisions into the new Gastrointestinal Solutions and Surgical and Interventional Solutions divisions, and has reallocated some corporate R&D and other expenses into these operating segments. Historical FY2025 figures have been restated to reflect the new structure and cost allocations, a move that will change segment-level profitability profiles but is intended to give investors clearer visibility into the performance of its main medical businesses.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2140.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Cuts Full-Year Guidance as Profit Slides Despite Stable Revenue

Olympus reported nine-month revenue to December 31, 2025 of ¥715.4 billion, down 1.4% year on year, with operating profit dropping 35.4% and profit attributable to owners of the parent falling 43.2%, reflecting weaker profitability in its continuing operations. Despite the earnings decline, total assets and equity both increased modestly, the company maintained a zero interim dividend but kept its full-year dividend forecast of ¥30 per share, and it revised its full-year earnings guidance downward while presenting results in ranges, signaling a more cautious outlook for fiscal 2026 amid ongoing portfolio adjustments and the addition of Swan EndoSurgical, Inc. as an equity-method affiliate.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2140.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Refreshes HR and Operations Leadership to Drive Next Phase of Global MedTech Transformation

Olympus announced upcoming leadership changes in its executive ranks, naming Simone Berger as Executive Officer and Chief Human Resources Officer and David Shan as Executive Officer and Chief Manufacturing and Supply Officer, effective April 1, 2026, pending formal board approval in March. The moves follow the decision of current CHRO Shigeto Ohtsuki and Chief Manufacturing and Supply Officer Tetsuo Kobayashi to step down after steering major reforms under the company’s Transform Olympus program, including job-based global HR systems, global talent placements, and the reorganization and optimization of manufacturing and supply chain operations. Olympus positions these appointments as the next phase of its transformation, with Berger expected to drive globally integrated HR processes, talent strategy, and culture change aligned with the company’s “Where Purpose Meets Performance” strategy, while Shan is tasked with shifting manufacturing and supply chain management from a region-centric to a business-centric model, advancing standardization, automation, and efficiency to support the new corporate strategy from April 2026 and underpin sustainable global growth.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2140.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Boosts Venture Fund with $150 Million Investment

Olympus Corporation has announced an additional investment of USD 150 million into its corporate venture capital fund, Olympus Innovation Ventures Fund II. This move is part of Olympus’s strategy to foster innovation and growth by building relationships with early-stage companies and nurturing partnerships with entrepreneurial teams. The investment aims to strengthen Olympus’s portfolio and support its expansion into new market segments, although it is not expected to have a material impact on the company’s financial results for the fiscal year ending March 31, 2026.

The most recent analyst rating on (JP:7733) stock is a Buy with a Yen2317.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.